Related Experiment Videos

The anti-arrhythmic effects of prednisone in patients with sarcoidosis

Amr Mohsen1

  • 1Department of Medicine, The George Washington University, Medical Center, Washington, DC 20037, USA. amr.mohsen@va.gov

Acta Cardiologica
|February 4, 2012
PubMed

Insights

Atrial fibrillation (AF) is a common heart rhythm disorder. A case study shows prednisone successfully treated AF caused by cardiac sarcoidosis, refractory to standard treatments.

Area of Science:

  • Cardiology
  • Immunology

Background:

  • Atrial fibrillation (AF) is the most common cardiac arrhythmia, with increasing prevalence due to an aging population.
  • Classical risk factors include hypertension, valvular disease, and thyroid disease, but etiology is often unknown.
  • Current treatments like medications and radiofrequency ablation (RFA) carry risks and may not always be effective.

Observation:

  • A patient presented with symptomatic AF refractory to multiple antiarrhythmic drugs and an RFA procedure.
  • The underlying cause of AF was identified as cardiac sarcoidosis, characterized by myocardial granulomatous involvement and systemic inflammation.

Findings:

  • Treatment with prednisone, a corticosteroid, led to the resolution of symptomatic AF.
  • This suggests a potential therapeutic role for anti-inflammatory agents in specific cases of AF.

Implications:

  • Cardiac sarcoidosis should be considered in patients with refractory AF of unknown etiology.
  • Corticosteroid therapy may be a viable option for AF associated with inflammatory conditions like sarcoidosis.
  • Further research is warranted to explore the link between systemic inflammation and cardiac arrhythmias.

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...